WVU Cancer Institute Annual Report 2017

PUBLISHED SPRING 2018

SIGNATURETHE

OUR MISSIONManage cancer in West Virginia and Appalachia by:

Providing state-of-the-art care to patients and their loved ones;

Dedicating ourselves to research, education, and service; and

Committing ourselves to address health disparities.

OUR VALUESQuality Innovation Teamwork Service Accountability

2 WVU Cancer Institute announces major expansion

4 Thoracic surgeon Ghulam Abbas, MD, brings robotics expertise to WVU Cancer Institute

5 WVU Cancer Institute opens regional cancer center at Reynolds Memorial Hospital in Glen Dale

SCREENING6 Bigger, better Bonnie’s Bus enters 10th year

DIAGNOSIS7 New cancer diagnoses in 2017

MULTIDISCIPLINARY CLINIC8 Transplant program named Program of Excellence

8 Comprehensive Breast Care Program continues high ranking

9 Clinical pharmacists bring expertise to the bedside

10 Up close and personal

SURGERY & RADIATION12 WVU Cancer Institute first in the nation to offer clinical trial and hope for lethal brain cancer

13 Conquering adversity

Contents

Notes5 New faces

6 Bonnie’s Bus 2017 summary

11 Multidisciplinary tumor boards

20 Academic programs at the WVU Cancer Institute

20 Continuing education opportunities

23 Mighty Mountaineer goes “all in” to fight cancer

23 WVU Cancer Institute Leadership Council

We’re all in this together

During my first year at WVU, I’ve been traversing the state and have met a lot of wonderful people who are deeply invested in improving the health of West Virginians. Our cancer burden is a heavy one here. Geographic barriers impede access to care. Unhealthy lifestyles, including tobacco use and obesity, promote the development of cancer. Too many of us fail to take advantage of anti-cancer vaccines, such as Human Papilloma Virus (HPV), which can prevent cervical and anal cancers.

We vigorously promote making cancer screening tests, like mammography and colonoscopy, more available because early detection vastly improves outcomes. We have work to do in cancer prevention, and last year, we implemented a new mobile mammography bus. This year, we will unveil a lung cancer screening bus. As a part of that effort, we have implemented a training program for tobacco treatment specialists who can work to reduce tobacco use. Our workforce also must contend with occupational exposures, such as breathing coal dust, that increase our cancer rates. Educating at-risk individuals to optimize their workplace safety is a high priority.

We’re encouraged that our outcomes for cancer treatment in Morgantown are comparable to outcomes in Pittsburgh or Philadelphia and better than the national averages. As we strive to bring that same level of care to the rest of the state, we unveiled in 2017 plans for a major, $13.2 million expansion of the WVU Cancer Institute. Construction of two new floors of the Mary Babb Randolph Cancer Center will be completed in May 2018, and we will open our doors this summer to accommodate growing demand for our specialized cancer services.

We’re also adding cancer specialists — a total of 38 specialists by 2020. Among our outstanding new physicians is Ghulam Abbas, MD, recently appointed director of surgical thoracic oncology and chief of thoracic surgery at WVU Medicine. Dr. Abbas specializes in robotic lung surgery that permits smaller incisions and faster recovery while providing optimal cancer outcomes.

In 2017, we also welcomed our first radiation oncology resident because we know that physicians who train in West Virginia are more likely to practice here.

Every week, we have a program that we call Science Exchange Fridays, which provides an interactive forum to jumpstart partnerships between our physicians and scientists. Progress against cancer requires a dialogue between experts across the spectrum of science, and these forums provide a crucible for generating new ideas and research endeavors.

WVU’s Clinical Trials Research Unit is introducing new opportunities for West Virginians to participate in cancer clinical trials whether they are cared for in Morgantown or by our other WVU cancer care providers, located in communities across the state. Our clinical researchers strive to bring cutting-edge research to WVU for our patients. For example, we were the first center in the US and one of only seven institutes worldwide to offer intraoperative radiation therapy (IORT) to treat glioblastoma, a lethal brain cancer. This technique allows the multidisciplinary team to treat the tumor bed during surgery after removal of the mass, protecting as much of the healthy brain as possible while targeting potential sites of residual tumor cells. WVU’s work in immuno-oncology is bringing our patients a more personalized treatment of their cancer and its genetic makeup. This summer, we expect to begin a specialized program of individualized immune treatment of lymphomas, known as Car-T therapy.

As we expand our network to places like Reynolds Memorial in Glen Dale and elevate the quality of care throughout the state, we are grateful for support from our fellow West Virginians, including generous donors to the Norma Mae Huggins Fund and other WVU Cancer Institute funds that are critical to furthering our mission. By engaging you, our community, in our work, we will make progress against cancer for ourselves, our loved ones, and our neighbors. We want to return people who develop cancer to health and restore their trajectory for long and productive lives. By working together, we can accelerate the pace of progress.

It’s good to know we’re all in this together as we continue the fight against cancer.

Richard M. Goldberg, MDDirector of the WVU Cancer InstituteLaurence S. and Jean J. DeLynn Chair of Oncology

BASIC & CLINICAL RESEARCH14 State’s first radiation oncology residency program could bring more cancer specialists to West Virginia

15 Looking beyond the laboratory

15 West Virginia “think tank” tackles multitude of cancer issues

16 From laboratory to bedside: Practicing strong science focused on real problems

17 Clinical Trials Research Unit brings groundbreaking cancer treatment trials to West Virginia

18 CTRU at a glance

SURVIVORSHIP20 A room of second chances

EDUCATION21 Tobacco-related disease risk still high among minorities

21 Cancer Burden Report builds on success

22 School of Dentistry ramps up fight against oral cancer

24 Publications

3Volume III 2018

The Signature

To improve patient care and provide cancer services for up to twice as many people in West Virginia, the WVU Cancer Institute announced in 2017 a massive expansion effort. It includes recruiting 38 new cancer specialists by 2020, as well as increasing space for patient care.

The Institute will also add more than 100 advanced practice providers, clinical pharmacists, nurses, medical assistants, and other clinical staff.

Clinic visits have increased by 27 percent at the WVU Cancer Institute Mary Babb Randolph Cancer Center in Morgantown in a year. “The WVU Cancer Institute has been on the front lines of WVU Medicine’s mission to address the real health problems facing our state by making world-class care available to a largely rural state,” Albert Wright, president and CEO of the West Virginia University Health System, said. “It was clear that this is an investment in the health of our state that we needed to make.”

The recruitment effort focuses on addressing the biggest cancer needs in the state – especially breast, prostate, lung, and colorectal cancers – in addition to growing the Institute’s more exclusive programs, such as intraocular melanoma, sarcoma, head and neck cancer, brain tumor, and Mohs surgery.

Renovations at the cancer center will add 32,000 square feet of patient care space. The $13.2 million project has an expected completion date of summer 2018.

said Richard Goldberg, MD, director of the WVU Cancer Institute.

WVU Cancer Institute announces major expansionWest Virginia’s leading cancer center to double specialists and space

Based on current growth rates, the projected increase in patient demand for services is anticipated to be approximately 20% per year over the next few years.

We want to elevate the quality of care locally,”

45

1 23

8

6

7

MARYLAND

PENNSYLVANIA

VIRGINIA

Brooke

Ohio

Marshall

Wetzel

Monongalia

Preston

Garrett (MD) Morgan

Berkeley

Jefferson

MineralHampshire

Hardy

GrantTucker

PendletonRandolph

Barbour

Taylor

Marion

HarrisonDoddridge

Ritchie

Tyler

Pleasants

Wood

Wirt

Jackson

Roane

Calhoun Gilmer

Lewis

Braxton

Clay Webster

Nicholas

Kanawha

Mason

PutnamCabell

Upshur

Hancock

1 Mary Babb Randolph Cancer CenterMorgantown, WV 304-598-4500 or 877-427-2894

2 Betty Puskar Breast Care CenterMorgantown, WV 304-293-8012

3 Berkeley Medical Center Regional Cancer CenterMartinsburg, WV 304-267-1944

4 Camden Clark Regional Cancer CenterParkersburg, WV 304-424-2256

5 WVU Cancer Institute at Garrett Regional Medical CenterOakland, MD 301-533-4222

6 Fairmont Regional Cancer CenterFairmont, WV 304-366-9999

7 Davis Medical Center Cancer Care CenterElkins, WV 304-637-3640

8 WVU Cancer Institute at Reynolds Memorial HospitalGlen Dale, WV 304-843-3302

Equally important is extending that care to communities throughout the state.

Dr. Goldberg explained, “Cancer outcomes in West Virginia are second-worst in the country, but around Morgantown, outcomes are as good as in Philadelphia or Pittsburgh. We’re trying to partner with institutions we contract with or purchase to share our expertise and make our level of care available closer to people’s homes. We are anxious to provide the kind of expertise some people feel compelled to leave the state to find.”

at one of the Institute’s growing number of regional centers. This year, the Institute forged a new relationship with the Davis Medical Center Cancer Care Center in Elkins and opened a new center at WVU Medicine Reynolds Memorial Hospital in Glen Dale, in addition to its existing centers in Morgantown, Martinsburg, Parkersburg, and Fairmont in West Virginia and Oakland, Maryland.

“

Greater numbers of West Virginians will be able to receive most of their care closer to home

LOCATIONS

with the highest mortality observed in lung, followed by colorectal and prostate cancers.

Cancer is now the leading cause of death in the state,

3rd highestcancer mortality

rate in the nation

#1in smoking prevalence

in the US

2 WVUMedicine.org/cancer

4 5WVUMedicine.org/cancer Volume III 2018

WVU Cancer Institute The SignatureNEW FACES

Austin Vargo, MDGabor Altdorfer, MD

Radiation Oncology

J. Wallis Marsh, MD(chair)

Kristen Lupinacci, DO

John Caruso, MD, MBAGhulam Abbas, MD

Valerie Galvan-Turner, MD

Surgery

Monika Holbein, MD Lauren Veltri, MD

Hematology/Oncology

The WVU Cancer Institute’s newest regional cancer center opened on the campus of Reynolds Memorial Hospital, Glen Dale, WV, in November 2017. The center offers diagnostic and consultative evaluation, intravenous and chemotherapy infusion, and laboratory services to people in the Northern Panhandle.

The Glen Dale center joins a network of seven other WVU cancer centers — in Morgantown, Martinsburg, Parkersburg, Fairmont, and Elkins in West Virginia, and Oakland, Maryland.

Although some patients may need to travel to Morgantown for surgery or other advanced procedures, most care, such as regular treatments and follow-up visits, can be received close to home at the new center.

“We believe strongly at the WVU Cancer Institute that cancer care is at its best when it’s done in partnership between specialists at an academic center and providers located in a patient's own community. The cancer center at Reynolds lets us do just that,” Richard Goldberg, MD, director of the WVU Cancer Institute, said.

He continued, “Patients at this center get WVU-quality care close to home with local access to selected clinical trials. When appropriate, they will get an expedited referral to the specialized services that are provided in Morgantown.”

The 3,606-square-foot clinic has two exam rooms, seven infusion rooms, and an American Cancer Society Resource Center and is staffed by a full-time WVU Cancer Institute physician and additional staff.

“Over my career, patients and families have consistently asked for cancer care to be brought to our community,” David Hess, MD, president and CEO of Reynolds Memorial Hospital, said.

“We are so fortunate to be a part of WVU Medicine’s mission to offer highly specialized cancer treatment to patients in the comfort and convenience of their hometown hospital. WVU Medicine Reynolds Memorial Hospital is committed to bringing world-class specialists from the academic center directly to our patients, so they can stay close to home for care. We feel that this is vitally important to meet the needs of the patients and their families.”

Eighty-year-old Jack Sayers is no stranger to cancer. The Elk Garden resident has seen two daughters battle breast cancer, and he lost his first wife to cancer 20 years ago. In March 2017, his hometown doctors confirmed that the nickel-sized spot on his lung was cancer.

Just 80 miles from his home, Ghulam Abbas, MD, surgical specialist in lung and esophageal cancers, had recently arrived in Morgantown from New Jersey to become director of surgical thoracic oncology and chief of thoracic surgery at WVU Medicine.

Sayers met with Dr. Abbas and, in April 2017, became Abbas’ first patient at WVU to have a robotic procedure to remove the upper left-hand lobe of his lung.

“We are one of the few centers in the world offering robotic lung-preserving surgery (called segmentectomy) for lung cancer,” Abbas said. “Segmentectomy is performed in patients with smaller lung cancer. It leaves more normal lung behind than a traditional surgical approach, so patients have fewer issues with breathing and have a better quality of life.”

Working through three small holes in Sayers’ chest, Abbas precisely guided tiny robotic “hands” and cutting instruments to remove the cancerous tissue.

Sayers commented, “It was an easy recovery. I never even took the pain pills they gave me — maybe a little Tylenol.”

He added, “I was never really scared. Dr. Abbas has a wonderful personality and

Thoracic surgeon Ghulam Abbas, MD, brings robotics expertise to WVU Cancer InstitutePatient cancer-free after robotic lung cancer surgery

is a great doctor. He told me not to worry about a thing and said, ‘I’ll treat you like I treat my family.’”

Sayers is among that group.

“I got up and was walking around just hours after my surgery,” he said. “I had a wonderful hospital stay.”

A year later, he’s feeling good and is cancer-free. He enjoys walking to visit his brother nearby and spending time with children, grandchildren, and great-grandchildren.

“Dr. Abbas saved my life. I’ve been blessed,” he said.

During his first year at WVU, Abbas performed a variety of minimally invasive surgeries to treat complex medical conditions, including lung and esophageal cancers, swallowing disorders, chest wall tumors, and conditions related to the thymus gland.

Abbas also is committed to screening and diagnostic programs that catch lung cancers early so he can give people with lung cancer a better chance for survival.

WVU Cancer Institute opens regional cancer center at Reynolds Memorial Hospital in Glen Dale

Abbas said 95 percent of his patients go home from the hospital within 48 hours with no pain.

Ghulam Abbas, MD

6 7WVUMedicine.org/cancer Volume III 2018

WVU Cancer Institute SCREENING DIAGNOSIS The Signature

communities it visits, according to Amy Allen, assistant director, WVU Cancer Institute Cancer Prevention and Control. In 2017, it reached 26 percent more women than it did just two years prior in 2015.

“From the beginning, the community linkage with Bonnie’s Bus has been, and always will be, part of what makes this program successful,” she said. Many communities hold fundraisers to support the program.

“We also couldn’t do this without our clinical partners around the state who help us provide a service to women who might not otherwise have access,” she added.

Bonnie’s Bus is a collaboration between the WVU Cancer Institute and WVU Medicine and serves all 55 counties in West Virginia. Since its launch in 2009, it has provided nearly 16,000 mammograms. Grant funds and donations are available for women without insurance coverage so that no woman age 40 or over is ever turned away.

To date, 73 women have been diagnosed with breast cancer following a screening on the Bus.

Learn more and view a calendar of upcoming stops WVUCancer.org/bonnie

BonniesBus

2017 Total since 2009

MAMMOGRAMS2,734 15,969

MILES18,960 144,582

VISITS147 940

As Bonnie’s Bus enters its 10th year, more and more women like these will benefit from the convenience and accessibility of West Virginia’s only mobile mammography unit. They’ll also benefit from a new, state-of-the-art, 45-foot bus, complete with a GPS system for navigating the state’s most rural areas.

The coach-style bus hit the road this summer and replaces the original Bonnie’s Bus, which was made possible through a donation from Ben and Jo Statler in honor of Jo’s mother, Bonnie Wells Wilson. It offers 3D mammography, the most advanced screening technology available, as well as greater privacy and comfort, including a wheelchair lift.

In addition, advanced cellular communications on the Bus allow mammogram images to be securely and electronically transmitted to the Betty Puskar Breast Care Center. As a result, women receive screening results faster, and the Bus can spend more time on the road serving patients instead of needing to regularly return to Morgantown to upload images.

The growth and success of Bonnie’s Bus is due in large part to the many

New cancer diagnoses in 2017

Bigger, better Bonnie’s Bus enters 10th year

CASES DETECTED9 73

Does not include Garrett Regional Medical Center, Davis Medical Center Cancer Care Center, and the WVU Cancer Institute at Reynolds Memorial Hospital. Data for 2016 not available at time of publication.

EYE & ORBIT | 7BONES & JOINTS | 5 SOFT TISSUE | 14

MYELOMA | 23

MISCELLANEOUS | 25ORAL CAVITY & PHARYNX | 60

LEUKEMIA | 71

ENDOCRINE SYSTEM | 83

LYMPHOMA | 69

FEMALE GENITAL SYSTEM | 64

URINARY SYSTEM | 99

BRAIN & OTHER NERVOUS SYSTEM | 135

DIGESTIVE SYSTEM | 233

RESPIRATORY SYSTEM | 273

BREAST | 309

MALE GENITAL SYSTEM | 130

SKIN (EXCLUDING BASAL & SQUAMOUS) | 99

20171,665

8 9WVUMedicine.org/cancer Volume III 2018

WVU Cancer Institute MULTIDISCIPLINARY CLINIC The Signature

The Cigna LifeSOURCE Transplant Network® has named the WVU Cancer Institute’s Osborn Hematopoietic Malignancy and Transplantation Program a Program of Excellence. This is the highest level awarded to transplant programs within the network, and WVU has achieved this level every year since 2014.

The Program of Excellence designation means WVU meets the highest quality standards and guidelines, including minimum volumes, types of transplants, and patient survival and disease status.

One of the nation’s leading transplant networks, Cigna LifeSOURCE contracts with select independent transplant facilities that are nationally recognized for their quality care. Membership includes more than 750 transplant programs at more than 160 independent transplant facilities.

The transplant program at WVU is

offering patients the latest treatments close to home.

As drug therapy options for cancer patients have continued to expand, so has the role of the hospital pharmacist. At the WVU Cancer Institute, oncology clinical pharmacists are direct members of the care team from the onset of diagnosis. They bring their expertise to the bedside, informing treatment decisions and medication adjustments in a timely, accessible process.

Oncology clinical pharmacists will commonly have a doctor of pharmacy (PharmD) degree and can receive two additional years of training to gain a deeper understanding of cancers and their treatments. They help decrease complications, readmissions, and medication errors, explained Aaron Cumpston, PharmD, BCOP, who rounds with the inpatient bone marrow transplant team.

Michael Craig, MD, section chief of oncology, explains the value of this expanded level of care.

he said. “The more providers helping the patient, the better the patient care is. Patients get safer chemotherapy and monitoring when a pharmacist is part of the care team.”

When Dr. Cumpston began his role at WVU Medicine 15 years ago, he was the only clinical pharmacist specialized in oncology. Today, the number of oncology pharmacists has grown significantly as the Cancer Institute continues to grow.

“We work in a very specialized manner, which allows us to have in depth understanding of a disease state and treatment approaches,” Cumpston explains. “We’re able to stay up-to-date and help treat patients with the latest therapies.”

Having clinical pharmacists integrated within the care team also means that medication adjustments can be made sooner if a dose needs to be changed.

“We can intervene and help patients receive the best personalized care with the best outcomes and least toxicity,” he said.

Cumpston’s counterpart in the outpatient setting is Megan Bodge, PharmD, BCOP. Dr. Bodge is very active in the outpatient management of transplant patients and is known to regularly leave her business card with them so she is accessible when they need her.

“I see a wide variety of health literacy in patients, and for many, it can all be very overwhelming,” she said. Complicating this is the increase in oral medications for patients to take at home. “We explain their treatment regimen in depth so they understand what they’re supposed to be doing.”

In addition to Cumpston and Bodge, clinical pharmacists are integrated into care teams covering blood/lymph cancers, breast cancer, lung cancer, gastrointestinal cancers, pediatric oncology, and palliative care, as well as supporting an investigational drugs team. They bring an added level of excellence and safety to patients.

The WVU Cancer Institute continues its reputation for nationally-recognized breast cancer care. Its Comprehensive Breast Care Program recently received a full three-year accreditation by the National Accreditation Program for Breast Centers (NAPBC). This is the breast care program’s third consecutive full accreditation.

Hannah Hazard, MD, surgeon in chief and director of clinical services at the Cancer Institute, noted that accreditation “helps patients come to us with confidence,

The NAPBC, which is administered by the American College of Surgeons, only grants accreditation to centers that have voluntarily committed to providing the highest level of quality breast care and that undergo a rigorous evaluation process and review of their performance.

The breast care program features a multidisciplinary team approach where patients see multiple specialists – breast surgeons and oncologists, genetic counselors, social workers, and clinical trial specialists – during one appointment. This collaborative care yields individualized treatment and helps patients get on the road to recovery sooner.

Transplant Program named Program of Excellence

Comprehensive Breast Care Program continues high ranking

knowing they’re getting nationally-recognized, high-quality care.”

PROGRAM OFExcellence

West Virginia’s only source for blood and bone marrow transplants,

Clinical pharmacists bring expertise to the bedside

“Patients benefit from a team approach to care,”

Michael Craig, MD

Megan Bodge, PharmD, BCOP

10 11WVUMedicine.org/cancer Volume III 2018

WVU Cancer Institute MULTIDISCIPLINARY CLINIC The Signature

Cancer cells reveal quite a bit of information under a microscope. Their size, shape, arrangement, and other characteristics help doctors diagnose cancer types and grades. But it’s the fine print the body stamps onto each person’s cancer – the DNA – that really tells the story and can help personalize treatment for improved outcomes.

This emerging science of molecular genomics recently expanded at the WVU Cancer Institute with the launch of a Personalized Molecular Profiling Tumor Board Conference. It’s led by Patrick Ma, MD, a clinician-scientist medical oncologist and co-leader of WVU’s Allen Lung Cancer Program. The conference occurs monthly – more often as needed – to ensure patients benefit from the latest in precision, or personalized, cancer therapy.

With tumor comprehensive molecular profiling, the goal is to guide therapy based on the molecular alteration, or gene mutation, that causes cancer in a specific person and potentially impacts how that cancer might respond to therapy options. Tumors that look the same under a microscope may have different gene mutations and therefore respond differently to treatment. By investigating each person’s unique genetic makeup, WVU doctors can prescribe the most personalized treatment for each person’s cancer.

The Personalized Molecular Profiling Tumor Board brings together the best WVU minds to gain insight into managing each patient’s cancer treatment. Members share knowledge so patients have a whole team of cancer experts behind their care. In addition, the tumor board serves as a forum for discussion and review of the latest scientific literature in precision oncology and immunotherapy, according to Dr. Ma.

“It brings together the multidisciplinary members of the Cancer Institute in a collective learning environment to foster discussion and collaboration in this new era of molecular genomics and precision cancer therapy,” he explained. Members include oncologists, hematologists, scientists, postdoctoral scholars and PhD students, pathologists, radiologists, pharmacists, and other caregivers and stakeholders.

The tumor board will provide a more uniform structure for advancing cancer treatment at WVU Medicine, according to Ma, and enhance current efforts that include:

A clinical trial focus on gene mutations that drive cancer rather than trials that focus on a specific type of cancer (such as breast or lung). This helps scientists understand cancer at a molecular level and zero in on genes that go wrong, which can illuminate therapies aimed at molecular targets rather than just focusing on a specific type of cancer.

Membership in the Caris Precision Oncology Alliance, which includes about 20 leading cancer centers that work collaboratively in research, clinical trials, and data sharing.

Participation in outcomes research for optimizing and validating the value of tumor molecular profiling and the emerging new frontiers.

“Tumor-molecular-profiling-guided therapy is becoming the emergent new standard of care in precision cancer therapy,” Ma said. “Before, patients would have to go to neighboring academic centers to receive these state-of-art therapies. Now, most of them are available here on site.”

Up close and personal

New tumor board conference boosts WVU

precision oncology

Multidisciplinary tumor boards

MLS (BLOOD CANCERS)Dr. Abraham Kanate

Hematologic Malignancy Tumor BoardsTo participate:

Janelle Humphrey-Rowan Janelle.humphreyrowan@wvumedicine.org / 304-598-9078

Multidisciplinary clinical team members include:(listed alphabetically)

Clinical trials coordinator

Data quality specialist

Dietitian

Gastroenterologist

Genetics counselor

Medical oncologist

Mid-level providers

Neuropsychologist

Nurse Navigators

Oncology quality coordinator

Pastoral care

Pathologist

Pharmacist

Physical therapist

Plastic surgeon

Radiation oncologist

Radiologist

Social services

Supportive care

Surgical oncologist

BREASTDr. Hannah HazardDr. M. Adham Salkeni

COMMUNITYDr. Michael Craig

THORACICDr. Patrick MaDr. Ghulam Abbas

SARCOMADr. Brock Lindsey

HEAD AND NECKDr. Tanya FancyDr. Mohammed Almubarak

Oncology Solid Tumor BoardsTo participate:

Sandy Malone malonesa@wvumedicine.org / 304-598-5429

Janelle Humphrey-Rowan Janelle.humphreyrowan@wvumedicine.org / 304-598-9078

UROLOGYDr. Tom Hogan

GASTROINTESTINALDr. Alan Thomay

BRAINDr. Aaron Provenzano

CUTANEOUS MALIGNANCIESDr. Inderjit Mehmi

GYNECOLOGICAL ONCOLOGYDr. Mohammed AshrafDr. Mohammed Almubarak

All tumor board meetings are held in the Mary Babb Randolph Cancer Center.

Patrick Ma, MD

12 13WVUMedicine.org/cancer Volume III 2018

WVU Cancer Institute The SignatureSURGERY & RADIATION

The WVU Cancer Institute is the first institution in the United States to offer intraoperative radiation therapy (IORT) to treat glioblastoma (a lethal form of brain cancer), which delivers a concentrated dose of radiation during surgery.

Physicians hope IORT will increase the time between initial treatment and recurrence, ultimately extending survival time and improving quality of life. Unfortunately, there are no current reliable treatments to stop the tumor from recurring. The average survival of glioblastoma is 14 to 20 months after treatment.

IORT delivers radiation immediately after a tumor has been removed. The radiation is applied directly to the affected area to kill any cancer cells lingering after surgery. The WVU Cancer Institute has used IORT to treat breast cancer for more than a year.

Usually without IORT, patients undergo surgery to remove the tumor, followed by external beam radiation three to five weeks after the surgery site has healed. Glioblastoma tumors virtually always recur within two centimeters of the original site, and tumors can regrow during the healing time between surgery and external beam radiation.

During his commencement speech at Gilmer County High School, Tyler Moore, class of 2017 valedictorian, told his classmates, “Persevere, my friends. The adversity that you face today will only make you stronger tomorrow.”

That statement held special significance for 18-year-old Moore, who has been battling a rare type of brain cancer for eight years.

Facial paralysis that began at age 9 was eventually diagnosed as paraganglioma, a rare tumor at the base of Moore’s skull. He traveled out of state for specialized care, including a 14-hour surgery. The cancer came back within a year and spread to his lungs. For the last seven years, oral chemotherapy has slowed the cancer’s growth.

This past summer, doctors prescribed six weeks of radiation therapy five days a week, which once might have required Moore to spend half his summer away from home, friends, and community.

Fortunately for Moore, WVU Cancer Institute established a Radiation Oncology program in 2012, which has grown to include six radiation oncologists and six physicists supported by state-of-the-art equipment for treating dozens of cancer types.

Austin Vargo, MD, radiation oncologist at the WVU Cancer Institute, encouraged his young patient to seek treatment in Morgantown, where he could live at home while receiving cancer care.

“People can remain engaged in their communities, can get their treatments closer to home, can continue their normal

WVU Cancer Institute first in the nation to offer clinical trial and hope for lethal brain cancer

Investigators hope the immediate and direct targeting of the tumor area with IORT will slow down cancer regrowth or possibly stop it.

“The real hope of the investigators and all of us that are involved in this clinical trial is that by decreasing lag time, being upfront and immediate, we will allow for a longer cessation of disease and maybe even overcome some of the progression,” Christopher P. Cifarelli, MD, PhD, WVU Medicine neurosurgeon, director of the WVU Gamma Knife Radiosurgery Program, and lead investigator for this clinical trial at the WVU Cancer Institute, said.

The clinical trial uses IORT as a boost to the current standard of care for glioblastoma. Dr. Cifarelli hopes to also examine using IORT to treat cancers that have metastasized to the brain from elsewhere in the body.

This treatment is through the INTRAGO-II study, an international FDA-approved clinical trial sponsored by University Medical Centre Mannheim in Germany.

This clinical trial is open to newly diagnosed glioblastoma patients who have not yet undergone any radiation therapy or chemotherapy.

Learn more Visit wvucancer.org/clinical-trialsE-mail cancertrialsinfo@hsc.wvu.edu

Conquering adversityHigh school valedictorian pursues dreams of medical career, despite cancer

lives with friends and family, but still know they’re receiving the same quality of care that they would receive anywhere else in the world,” Dr. Vargo said.

The department offers Gamma Knife radiosurgery for brain cancer, intraoperative radiation therapy for breast cancer, and several other advanced radiation therapy techniques, such as image-guided radiation therapy, intensity-modulated radiation therapy, and stereotactic body radiation therapy.

In between radiation treatments, Moore spent his summer volunteering as an emergency medical technician (EMT) in his hometown of Glenville. He’s now pursuing studies in biology and chemistry at Glenville State College, with hopes of attending medical school and practicing medicine in West Virginia.

As he revealed in his valedictory speech, “I didn’t expect to have cancer.

“Nevertheless, these impending obstacles and trials do not mean that we should just quit and never try to pursue our dreams.”

“He wants to continue to progress the healthcare mission within rural West Virginia,” Dr. Vargo said. “That’s really an impressive combination that highlights the power of perseverance and strength through adversity.”

Above: Tyler Moore graduated valedictorian of the Gilmer County High School class of 2017. Below: Austin Vargo, MD, talks with Tyler about possible futures in the medical field.

Christopher P. Cifarelli, MD, PhD, WVU Medicine neurosurgeon and director of the WVU Gamma Knife Radiosurgery Program, during an IORT procedure

The WVU Cancer Institute is one of only seven institutions worldwide currently involved in the clinical trial.

WVU Cancer Institute has removed some of the obstacles to Moore’s dreams and allowed him to contribute his skills to his local community.

14 15WVUMedicine.org/cancer Volume III 2018

WVU Cancer Institute BASIC & CLINICAL RESEARCH The Signature

Rural states like West Virginia often have shortages of highly trained specialist physicians. When graduating medical students need to relocate to out-of-state residency programs, they frequently build relationships that encourage them to practice in the area where they trained. In 2017, the WVU Department of Radiation Oncology established the state’s first radiation oncology residency program. Doctors at WVU are confident that medical residents who train by caring for West Virginians will be more likely to practice here as well.

“More than one of the candidates who visited WVU cited our cooperative, collaborative environment here as the reason they’re interested in coming to WVU. Success here is based on working really well with other physicians rather than competing with them,” said Todd Tenenholz, MD, PhD, radiation oncology residency program director.

Dr. Tenenholz, a board-certified radiation oncologist, came to the WVU Cancer Institute in 2016 following 10 years at Vanderbilt. Establishing a radiation oncology residency program was a top goal for WVU, and he praises the teamwork that helped him get the residency program up and running in just one year.

The four-year program brought on its first resident in July 2017, and a second resident will start in 2018. The residency emphasizes in-depth training in using the latest radiation oncology tools and techniques to manage patients’ cancer. Residents also spend time with related specialists, such as surgeons and radiologists. They are encouraged to pursue research, some of which could help find solutions to cancer issues in West Virginia.

State’s first radiation oncology residency program could bring more cancer specialists to West Virginia

While investigating possible links between obesity and breast cancer, researcher Linda Vona-Davis, PhD, co-director of the WVU Cancer Institute’s Cancer Cell Biology Biomedical Research Program, frequently consults with surgical and medical oncologists to unlock the mysteries of cancer.

She encourages that same kind of collaboration among her PhD students, and she thinks it is critical for the next generation of cancer scientists to work closely with colleagues who provide direct patient care.

“Lab-based researchers need to be exposed to clinical cancer as much as clinically based care deliverers need to update themselves on advances that will eventually impact patient care,” she said. “It’s a partnership that will improve our knowledge and accelerate discovery from bench to bedside. Laboratory research is moving toward more team science, and the oncologists are the conduit for the translation of laboratory discoveries.”

For example, Vona-Davis explained, oncologists still don’t know everything about the genetic changes that occur in cancer cells. The molecular profiling of tumors becomes important work for oncologists and cancer biologists to discover new treatment options for a patient. Although cancer biology students don’t interact directly with patients, they are searching for genetic clues

Looking beyond the laboratoryCancer scientists gain valuable insights from colleagues caring for patients

West Virginia “think tank” tackles multitude of cancer issuesCommitted to solving the mysteries of cancer, WVU’s talented physicians, researchers, population scientists, and others come together weekly for the WVU Cancer Institute Science Exchange. Approximately 60 experts and their trainees gather to present research, diagnostic and treatment challenges, and discuss new approaches or solutions. Monthly, smaller groups get together to work on more specific disease-focused topics.

“Cancer is a really challenging and diverse set of diseases – not just one type of illness as people sometimes imagine,” said Laura Gibson, PhD, deputy director of the WVU Cancer Institute and senior associate vice president for Research and Graduate Education at the WVU Health Sciences Center.

About half of all people with cancer receive some type of radiation therapy during their treatment. Radiation oncologists use precisely targeted, high-energy radiation to destroy cancer cells and spare healthy cells as much as possible. The treatment can be used alone or in combination with surgery, chemotherapy, or immunotherapy.

“The complexity of this specialty has grown exponentially,” Tenenholz said.

He also notes how the residency increases opportunities to integrate all fields that touch cancer patients, including surgery, medical oncology, pathology, and radiology.

Tenenholz added, “As we think about how we’re going to teach our residents, we’re challenged to be up to date and really understand every aspect of the treatment.”

WVU’s six radiation oncologists are prepared to set a high standard as they train the next generation of specialists.

Having the residency means there’s going to be a supply of highly trained radiation oncologists in West Virginia — and they’ll be much more likely to stay here if we train them.”

“

to the growth and progression of cancer using tumor samples donated by cancer patients and public databases.

Vona-Davis and her colleagues published an article in the September 2017 issue of the journal Cancer Research on enhancing cancer cell biology students’ knowledge of clinical oncology. Students and faculty nationwide completed electronic surveys regarding methods of integrating clinical oncology into

PhD cancer cell biology programs. It provided recommendations for the best ways to make that happen.

“Surgeons and medical and radiation oncologists from our cancer medical center often help guide our students’ research,” Vona-Davis remarked. “The clinicians participate in journal clubs to give a patient-care perspective and invite students to multidisciplinary tumor boards to discuss patient cases. Interactions like this promote team science and cross training.”

As Vona-Davis and her colleagues concluded in their paper, “Integrating the basic science and clinical research communities in particular is of increasing importance for rapid translation of studies into clinical practice with the goal of improving patient outcomes.”

“Our topics at the CI Science Exchange can be as specific as discussion of a single protein that may be relevant in many types of cancer or as broad as the side effects of certain treatments of cancer in patients in our clinic,” she continued. “Real problems are never solved individually. Improving our understanding of cancer is definitely an area that requires the ‘wisdom of the crowd’ to make any real progress.”

Colleagues learn from each other: Scientists in the laboratory gain better understanding of what clinicians face every day with their patients. Physicians continue to learn about their scientific colleagues’ capabilities to tackle problems in the lab and formulate new diagnostic or therapeutic strategies. The population-focused scientists emphasize thinking beyond individual patients to the needs of broader groups of people across the state.

Dr. Gibson remarked, “The CI Science Exchange is just one example of how dedicated the WVU Cancer Institute team is to solving problems together to improve health and patient outcomes. Caring about people doesn’t just happen in the clinic – it is felt as strongly in our laboratories and out in the communities.”

Todd Tenenholz, MD, PhD

16 17WVUMedicine.org/cancer Volume III 2018

WVU Cancer Institute BASIC & CLINICAL RESEARCH The Signature

Behind every new cancer treatment are cancer patients willing to be part of a clinical trial to test the latest advance. The WVU Cancer Institute is providing abundant opportunities for participation, and West Virginians are doing their part for cancer research.

In 2017, 156 people enrolled in clinical trials in the WVU Cancer Institute network,

“Clinical trials at our cancer centers allow us to provide the most innovative treatment for patients,” said Anne Schnatterly, BSN, RN, CCRP, director of the WVU Cancer Institute Clinical Trials Research Unit. “Using new cancer drugs compared to the old drugs is like having a smart phone instead of a rotary phone.”

She continued, “One of our largest accomplishments in recent years is not just bringing innovative trials to patients but bringing research close to their homes at our locations across the state, such as Camden Clark in Parkersburg, Berkeley in Martinsburg, and soon Reynolds Memorial in Glen Dale, in addition to the Mary Babb Randolph Cancer Center.” (See Reynolds Memorial story on page 5.)

Schnatterly’s 23-member staff of nurses, lab technicians, and data and regulatory coordinators collaborates with WVU investigators — medical oncologists, radiation oncologists, surgeons, and

Clinical Trials Research Unit brings groundbreaking cancer treatment trials to West Virginia

pharmacists — to enroll patients in cancer treatment studies for virtually all cancers common to West Virginians. The most prevalent include breast, lung, and leukemia/lymphoma.

WVU participates in government-sponsored and industry-sponsored studies, but Schnatterly is proudest of studies initiated by WVU researchers. For example, radiation oncologist Malcolm Mattes, MD, is studying whether giving a small dose of radiation at the site of a lung cancer can improve the effects of that patient’s immunotherapy treatment (treatment that stimulates the body to fight cancer).

National and state organizations are noticing WVU’s contributions. In 2016 and 2017, the National Cancer Institute’s National Clinical Trials Network recognized WVU for its high patient enrollment in clinical trials and its high-quality data collecting and reporting.

As director of the West Virginia Clinical Trials Network, Schnatterly is working hard to bring additional clinical trials to the state, particularly industry-sponsored trials.

“My passion since arriving in the state 3 ½ years ago is to have industry see we have this special group of patients with limited access to care who want to take part in groundbreaking studies,” she said.

“We want to offer them more options at more locations and give them hope in beating their disease.”

Imagine Coach Bob Huggins drawing up plays for the WVU men’s basketball team but never talking to the players who will execute them. In a similar way, cancer researchers in a laboratory can’t contribute what’s most relevant to their field if they don’t talk to the physicians who are diagnosing and treating patients daily.

said Laura Gibson, PhD, deputy director of the WVU Cancer Institute and senior associate vice president for Research and Graduate Education at the WVU Health Sciences Center. “We take on everything as a team, and our partnerships underpin any of the work we do to generate new knowledge to improve the health and outcomes of our patients.”

She noted that West Virginians throughout the Appalachian region are benefiting from the collaboration in tangible ways. Scott Weed, PhD, researcher and associate professor for the WVU Cancer Institute, works with head and neck cancer specialist Rusha Patel, MD, regularly on projects to optimize and elevate the level of patient care.

A new project they are proposing is designed to improve identification of where the cancer tissue ends and healthy tissue begins in WVU patients who have tumors in the mouth and throat. If approved, the practice during surgery would be to apply a specialized tumor-binding dye to the cancer site after the

From laboratory to bedside: Practicing strong science focused on real problems

tumor is cut out. A hand-held lamp would provide rapid and easy detection of residual tumor tissue. That extra step could facilitate more complete surgical removal of the cancer.

Another partnership between Dr. Weed and pathologist James Coad, MD, has researchers in the lab identifying whether there are unique features of head and neck tumors in West Virginia patients as compared to people in other parts of the country.

If they find distinctive features, “we then get that information into hands of clinicians like Dr. Patel to see if we can use existing drugs designed for other cancers to treat them or design new drugs to help our patient population,” Weed explained.

Dr. Gibson summarized, “Clinical and basic science interactions allow the scientist to understand the fundamental unanswered questions that remain important in the clinic. Importantly, the discussions also provide insight into the most relevant experimental design of preclinical studies because they are modeled as closely as possible to resemble what our physician colleagues describe to us.

(See previous for related article on how WVU’s Cancer Cell Biology Program incorporates basic and clinical science.)

“Collaboration between basic, clinical, and population scientists is a strength of the

WVU Cancer Institute,”

Teamwork always results in the strongest science with the best potential to solve real problems.”

a 50 percent increase from the average enrollment over the prior three years.

Laura Gibson, PhD

Anne Schnatterly, BSN, RN, CCRP

18 19WVUMedicine.org/cancer Volume III 2018

Brooke (WV)

Ohio (WV)

Marshall

WetzelMonongalia

Preston

Garrett (MD)

Allegany (MD)

Morgan

Berkeley

Jefferson (WV)

MineralHampshire

Hardy

GrantTucker

Pendleton

Randolph

Barbour

Taylor

Marion

HarrisonDoddridge

Ritchie

Tyler

Pleasants

Wood

Wirt

Jackson

Roane

CalhounGilmer

Lewis

Braxton

Clay Webster

PocahontasNicholas

Greenbrier

MonroeSummers

MercerMcDowell

Wyoming

Raleigh

Fayette

Kanawha

Mason

Putnam

Cabell

Wayne

MingoLogan

Boone

Lincoln

Upshur

Greene (PA)Fayette (PA)

Hancock (WV)

MARYLAND

OHIO

PENNSYLVANIA

Somerset (PA)

ESOPHAGUS | 1

The West Virginia University Clinical Trials Research Unit (CTRU) conducts clinical trials at the WVU Cancer Institute, as well as at the WVU Health Sciences Center. Based in Morgantown, the unit is dedicated to providing the services and expertise that investigators need to conduct clinical trials focused on improving the treatment of cancer. The CTRU offers cancer clinical trials in virtually all cancers common to West Virginians and has received several Commission on Cancer commendations for regularly exceeding the national standard for percentage of patients enrolled in clinical trials.

2016-2017

National Avg.3%

WVUCI9% (152)

Total new patients

1,665New patients enrolled

in therapeutic trials2017

CTRU AT A GLANCE

New patients in therapeutic trials by cancer type

BREAST | 61

LEUKEMIA | 26

LUNG | 28

LYMPHOMA | 12

MELANOMA | 9

MULTIPLE MYELOMA | 3

PROSTATE | 4RECTUM | 2

OVARY | 3PANCREAS | 1

SARCOMA | 1

BRAIN | 4URINARY BLADDER | 2

PATIENTS IN CLINICAL TRIALS

BY COUNTY

1–4

5–910–14

>25 MORGANTOWN, WV

WVU CANCER INSTITUTE FLAGSHIP

Maryland Pennsylvania Tennessee

19% of participants in new trials are out-of-state

Shelby County, Tennessee, not shown

KIDNEY | 1

20 21WVUMedicine.org/cancer Volume III 2018

WVU Cancer Institute SURVIVORSHIP EDUCATION The Signature

A National Cancer Institute (NCI) report led by WVU public health expert Linda Alexander shows that despite a drop in cigarette smoking nationwide, minority groups are at higher risk for tobacco-related diseases than others. The study represents the most comprehensive review of tobacco use among minority groups since a 1998 Surgeon General report.

Alexander, associate dean of academic affairs for the WVU School of Public Health and professor of social and behavioral sciences, investigates tobacco-related health disparities and was the report’s senior editor.

According to Alexander, before the 1998 Surgeon General report, the prevailing attitude was, “Since all tobacco is bad, why distinguish between how it affects some populations versus others?” She continued, “What we know from working in this field for a number of years is that it’s all bad, but its burden is different for some groups.”

The new report reveals that smoking cessation trials and tobacco-use data collection efforts often do not fully represent minority groups. Specifically, racial and ethnic minorities, members of the LGBTQ community, and low-socioeconomic-status women and girls have been slow to benefit from evidence-based practices that reduce cigarette smoking.

In their cases, the “needle hasn’t moved far enough for us to discontinue our

Cancer Burden Report builds on success

focus on these and other populations,” Alexander said.

Besides emphasizing the need for more focus on how socially disadvantaged groups take up, try to stop, and are affected by smoking, the new report also affirms the importance of having scientific investigators who are familiar with, or even come from, underrepresented groups being studied.

Alexander herself is the first African American to serve as senior editor for a volume in the NCI’s Tobacco Control Monograph series, which began its run in 1991 and published the report.

The WVU School of Public Health is home to the West Virginia Prevention Research Center, one of 26 funded by the Centers for Disease Control and Prevention (CDC). Alexander will work with the Research Center to share the study with other CDC prevention research centers across the country.

The report will help inform policies, programs, and partnerships with communities that are most affected by tobacco-related health disparities. Additionally, it will serve as a resource for future research, including additional exploration of how tobacco use affects people who are part of two or more disadvantaged groups.

“For some populations,” Alexander said, “the way we gather information is as salient as what we do with it.”

Following the success of its user-friendly 2016 West Virginia Cancer Burden Report, the WVU Cancer Institute’s Cancer Prevention and Control (CPC) was awarded a contract by the West Virginia Department of Health and Human Resources to produce the report for the next three years. The 2017 report, created in collaboration with the West Virginia Cancer Registry, is now available.

provides data for policy decisions, identifies needs for cancer prevention and control efforts, and better targets resource allocation,” said Stephenie Kennedy, EdD, CPC director. “Our ultimate goal through this report is to reduce the impact of cancer in West Virginia.”

Easy-to-follow tables, charts, and infographics communicate the cancer burden, including trends in cancer incidence and mortality, in West Virginia at the state and county level. In addition to these statistics, the report provides a new section on HPV-related cancers as well as information and resource pages on cancers that have screening tests available, including breast, cervical, colorectal, and lung cancers.

View the report WVUCancer.org/cancer-prevention-control

Tobacco-related disease risk still high among minorities

NCI study led by WVU public health expert to aid in prevention

“Information in this report influences cancer research,

Continuing Education Opportunities

Academic programs at the WVU Cancer Institute

Lung Cancer Screening in WV CME Webinar – available online under Web Courses at ce.wvu.edu

Women’s Health Information Programs – May 10 & 15

Understanding Cancer and Patient Navigation – August 2

Fourth Annual WVUCI Breast Cancer Conference – August 3

28th Annual Fall Cancer Conference – October 28

2018 Lung Cancer Conference: Catalyzing Change to Address Lung Cancer – November 1-2

CANCER CELL BIOLOGY GRADUATE PROGRAM The WVU Cancer Cell Biology Graduate Program trains PhD and MD/PhD candidates to be cancer researchers. It provides a strong foundation in cell biology, oncogenes and signaling networks, tumor microenvironment, bioinformatics, and chemotherapeutics learned through course work and laboratory training.

HEMATOLOGY/ONCOLOGY FELLOWSHIP WVU Hematology/Oncology fellows develop clinical expertise in cancer therapy, acquire knowledge of basic biology of neoplastic diseases, and carry out research on problems in Hematology/Oncology. Fellows see a variety of complex patients and work in inpatient, clinic, and research settings.

ONCOLOGY PHARMACY RESIDENCY The WVU Oncology Pharmacy Residency provides experience in hematologic malignancy, solid tumor oncology, bone marrow transplant, ambulatory oncology, investigational drug pharmacy, research, and palliative care.

RADIATION ONCOLOGY RESIDENCY PROGRAM The Radiation Oncology Residency Program emphasizes in-depth training in using the latest radiation oncology tools and techniques to manage patients’ cancer. Residents also spend time with related specialists, such as surgeons and radiologists. They are encouraged to pursue research, some of which could help find solutions to cancer issues in West Virginia.

RADIATION THERAPY PROGRAM The Radiation Therapy Program at the WVU Cancer Institute is a 12-month certificate program for radiographers. Student therapists obtain clinical experience in radiation treatment techniques, CT simulation, treatment planning, and brachytherapy implants.

UNDERGRADUATE SUMMER RESEARCH FELLOWSHIP PROGRAM The Mary Babb Randolph Cancer Center offers undergraduate research fellowships in clinical and basic cancer research. The highly competitive 10-week fellowship program provides funding and opportunities for students who want to pursue careers in cancer research.

They come to give thanks, share laughter, tell stories, and find hope. They are cancer survivors. And they are some of the strongest people on earth. About 500 cancer survivors and their caregivers attended the annual Survivor’s Day Celebration Aug. 13 at Lakeview Golf Resort and Spa in Morgantown.

WVU Cancer Institute Director Richard Goldberg, MD, told the group that it was a great day to be a cancer survivor. Just two decades ago, he said, the number of cancer survivors was much smaller and could have fit inside the lobby.

The event was a welcome opportunity for survivors to thank their doctors, nurses, social workers, and so many others involved in their care.

Helen Morris of Grantsville, a 12-year breast cancer survivor, loved the pervasive laughter, which could be heard in every corner of the room. Dorothy Wilkins of Mt. Morris, Pennsylvania, is in her first year of lung cancer survivorship and appreciated the hope she felt from seeing so many cancer survivors.

From hope to laughter, the event unites area cancer survivors in a unique spirit of fellowship.

A room of second chances

Today, more cancer survivors are getting second chances at life.

Cancer survivors and care providers enjoy a meal at the annual Survivor’s Day Celebration.

22 WVUMedicine.org/cancer

WVU Cancer Institute EDUCATION

To learn the many ways you can help the WVU Cancer Institute advance cancer care across the region, please visit WVUCancer.org/give.

Mighty Mountaineer goes “all in” to fight cancer

This group of highly committed volunteers supports the Cancer Institute through advocacy and professional expertise and guidance. Members also serve as ambassadors for philanthropic and community linkages and partnerships. Currently serving on the council are:

Jo Statler Chairperson

William BrightJames ChamberlainDiane Dailey

Gregory DarbyJenny Dinsmore

(emeritus)

Meredith GermanDiane Lewis-Jackson

“The reason I give is because I can, so I do.” It’s that simple for WVU Cancer Institute supporter Greg Darby, president and co-owner of Little General Stores. His giving philosophy also extends to Little General, which often supports communities in which it has stores.

About 11 years ago, Darby met someone who shared a similar philosophy – WVU Men’s Basketball Coach Bob Huggins.

As their friendship grew, Darby learned of the Norma Mae Huggins Cancer Research Endowment Fund, which Coach Huggins established in 2003 in memory of his mother, who died from colon cancer.

Cancer also has touched Darby’s own family. “I feel cancer is the right thing to support. A lot of my friends have died from cancer. So I’m doing this for cancer and for Huggs.”

When the Cancer Fund wasn’t growing at the rate Huggins had hoped, Darby began brainstorming with him for a larger event to replace multiple fundraisers. They both loved to fish. So in 2013, the Bob Huggins Fish Fry was born.

Today, the fund has grown to about $2.4 million, including more than $300,000 raised at the 2018 event. In addition to committing Little General Stores as an annual major sponsor for the Fish Fry, Darby also makes personal contributions to the fund.

The support doesn’t stop there for this lifelong West Virginian.

When Huggins achieved his 800th win last year, Darby thought of another way to raise funds. He had received countless calls from people wanting a pullover jacket bearing the Little General logo

like the one he’d given Huggins years prior. So he and others started the 800 Club, which, among other membership perks, includes a limited-edition, similarly-designed pullover jacket. Darby estimates the 800 Club has raised another $300,000 to $400,000 for the fund.

In addition to raising funds for cancer research, Darby, a WVU alum, recently joined the WVU Cancer Institute Leadership Council. He also supports WVU Medicine Children’s and WVU Athletics.

“I think I do my part,” Darby chuckled. “I want to be part of what we’re building. Better doctors, better facilities. I think it’s great for West Virginia and the University, and people won’t have to leave the state to beat cancer.”

David McCormick, Jr.Barbara Alexander

McKinneyMary McKinleyWilliam Pulice

WVU Cancer Institute Leadership Council

Betty PuskarPhil RealeKathleen RichardsSharon Rowe

Alison Bibbee SmithJoan StampShirley Weaver

(emeritus)

JOIN US

The WVU School of Dentistry has received accreditation to implement a tobacco treatment specialist (TTS) training program aimed at reducing tobacco use and oral cancer incidence. This makes WVU one of only 18 education and health institutions nationally that are accredited by the Council for Tobacco Treatment Training Programs (CTTTP).

More than a quarter of West Virginia adults smoke, notes a United Health Foundation 2016 America’s Health Rankings annual report. Between 2009 and 2013, 4,240 deaths in the state were attributed to diseases and complications related to smoking, according to the West Virginia Department of Health and Human Resources.

“The number one risk factor for periodontal disease is smoking, and

School of Dentistry ramps up fight against oral cancerTraining program to begin for tobacco treatment specialists

tobacco is the number one link to oral cancer,” said Susan Morgan, DDS, who will lead the TTS training program.

A faculty member at WVU, Dr. Morgan has been working since 2000 to educate dentists on how to help patients understand the risks and consequences of tobacco use and end their nicotine dependency. She approached the CTTTP with the goal of training myriad healthcare providers, not just dental professionals.

“If this is going to work, we’ve all got to work together. I‘ve got to be able to call a pharmacist and say, ‘I want this patient on a combination of cessation medications,’” Morgan explained. In 2013, the Federal Drug Administration published information indicating combination pharmacotherapy is extremely important and effective in helping tobacco users quit.

A 26-member multidisciplinary team, developed by the School of Dentistry and the WVU Health Sciences Center Office of Interprofessional Education, will execute the training program, set to begin in 2018. Team members include representatives from the School of Pharmacy, School of Public Health, School of Nursing, School of Medicine, School of Dentistry, WVU Cancer Institute, and others.

“We’re going to reach out to all healthcare providers who deal with a population of tobacco users,” Morgan added. “The program will teach participants evidence-based means of treatment that are known to work.” This will include a combination of medicine and behavior therapy to be individualized for each nicotine-addicted patient.

Dr. Susan Morgan (left) collaborates with WVU School of Dentistry students Mannhu Iglesias and Andrew Marra after a morning

of work in the student clinic.

23Volume III 2018

24 25WVUMedicine.org/cancer Volume III 2018

WVU Cancer Institute EDUCATION The Signature

FLUORESCENCE AND SENSING APPLICATIONS OF GRAPHENE OXIDE AND GRAPHENE QUANTUM DOTS: A REVIEW. CHEMISTRY, AN ASIAN JOURNAL. Zheng P, Wu NQ

SIRT1-DEPENDENT ANTI-SENESCENCE EFFECTS OF CELL-DEPOSITED MATRIX ON HUMAN UMBILICAL CORD MESENCHYMAL STEM CELLS. JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE. Zhou L, Chen X, Liu T, Zhu C, Si M, Jargstorf J, Li M, Pan G, Gong Y, Luo ZP, Yang H, Pei M, He F

BONE CANCEROSTEOBLAST DIFFERENTIATION AND BONE MATRIX FORMATION IN VIVO AND IN VITRO. TISSUE ENGINEERING. PART B, REVIEWS. Blair HC, Larrouture QC, Li Y, Lin H, Beer Stolz D, Liu L, Tuan R, Robinson LJ, Schlesinger PH, Nelson DJ

A SELECTIVE CELL POPULATION FROM DERMIS STRENGTHENS BONE REGENERATION. STEM CELLS TRANSLATIONAL MEDICINE. Wang T, He J, Zhang Y, Shi W, Dong J, Pei M, Zhu L

BRAIN CANCEREARLY VERSUS LATE GAMMA KNIFE RADIOSURGERY FOLLOWING TRANSSPHENOIDAL SURGERY FOR NONFUNCTIONING PITUITARY MACROADENOMAS: A MULTICENTER MATCHED-COHORT STUDY. JOURNAL OF NEUROSURGERY. Pomeraniec IJ, Kano H, Xu Z, Nguyen B, Siddiqui ZA, Silva D, Sharma M, Radwan H, Cohen JA, Dallapiazza RF, Iorio-Morin C, Wolf A, Jane JA, Jr., Grills IS, Mathieu D, Kondziolka D, Lee CC, Wu CC, Cifarelli CP, Chytka T, Barnett GH, Lunsford LD, Sheehan JP

BREAST CANCERINHIBITION OF VEGF AND ANGIOPOIETIN-2 TO REDUCE BRAIN METASTASES OF BREAST CANCER BURDEN. FRONTIERS IN PHARMACOLOGY. Bohn KA, Adkins CE, Nounou MI, Lockman PR

IMPACT OF PATIENT RACE AND GEOGRAPHICAL FACTORS ON INITIATION AND ADHERENCE TO ADJUVANT ENDOCRINE THERAPY IN MEDICARE BREAST CANCER SURVIVORS. MEDICINE. Camacho FT, Tan X, Alcala HE, Shah S, Anderson RT, Balkrishnan R

CANCER RISK INFORMATION SHARING: THE EXPERIENCE OF INDIVIDUALS RECEIVING GENETIC COUNSELING FOR BRCA1/2 MUTATIONS. JOURNAL OF HEALTH COMMUNICATION. Chopra I, Kelly KM

AXILLARY LYMPH NODE COVERAGE WITH 3-DIMENSIONAL TANGENTIAL FIELD IRRADIATION AND CORRELATION WITH HEART AND LUNG DOSE. ADVANCED RADIATION ONCOLOGY. Jacobson GM, Bunda-Randall N, Wen S, Miller M

LOW-ENERGY INTRAOPERATIVE RADIATION THERAPY AND COMPETING RISKS OF LOCAL CONTROL AND NORMAL TISSUE TOXICITY. FRONTIERS IN ONCOLOGY. Jacobson GM, Siochi RA

DISPARITIES IN THE INITIAL LOCAL TREATMENT OF OLDER WOMEN WITH EARLY-STAGE BREAST CANCER: A POPULATION-BASED STUDY. JOURNAL OF WOMEN’S HEALTH. LeMasters TJ, Madhavan SS, Sambamoorthi U, Vyas AM

TARGETING THE STEM CELL PROPERTIES OF ADULT BREAST CANCER CELLS: USING COMBINATORIAL STRATEGIES TO OVERCOME DRUG RESISTANCE. CURRENT MOLECULAR BIOLOGY REPORTS. Margaryan NV, Seftor EA, Seftor REB, Hendrix MJC

QUANTITATIVE FLUORESCENT MICROSCOPY TO MEASURE VASCULAR PORE SIZES IN PRIMARY AND METASTATIC BRAIN TUMORS. CANCER RESEARCH. Mittapalli RK, Adkins CE, Bohn KA, Mohammad AS, Lockman JA, Lockman PR

METASTATIC BREAST CANCER: ENDOCRINE THERAPY LANDSCAPE RESHAPED. AVICENNA JOURNAL OF MEDICINE. Salkeni MA, Hall SJ

GEOGRAPHIC DISPARITIES IN ADHERENCE TO ADJUVANT ENDOCRINE THERAPY IN APPALACHIAN WOMEN WITH BREAST CANCER. RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY. Tan X, Camacho TF, Marshall VD, Donohoe J, Anderson RT, Balkrishnan R

TRASTUZUMAB DISTRIBUTION IN AN IN-VIVO AND IN-VITRO MODEL OF BRAIN METASTASES OF BREAST CANCER. ONCOTARGET. Terrell-Hall TB, Nounou MI, El-Amrawy F, Griffith JIG, Lockman PR

RANDOMIZED PHASE II STUDY OF RAMUCIRUMAB OR ICRUCUMAB IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC BREAST CANCER. THE ONCOLOGIST. Vahdat LT, Layman R, Yardley DA, Gradishar W, Salkeni MA, Abraham JA, Garcia AA, Ward P, Khatcheressian J, Sparano J, Rodriguez G, Tang S, Gao L, Dalal RP, Kauh J, Miller K

IDENTIFICATION OF NOVEL AGENTS FOR THE TREATMENT OF BRAIN METASTASES OF BREAST CANCER. CURRENT CANCER DRUG TARGETS. Venishetty VK, Geldenhuys WJ, Terell-Hall TB, Griffith JI, Sondag GR, Safadi FF, Lockman PR

DIFFERENCES IN MEDICARE EXPENDITURES BETWEEN APPALACHIAN AND NATIONALLY REPRESENTATIVE COHORTS OF ELDERLY WOMEN WITH BREAST CANCER: AN APPLICATION OF DECOMPOSITION TECHNIQUE. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. Vyas A, Madhavan SS, Sambamoorthi U

HEALTHCARE UTILIZATION AND COSTS DURING THE INITIAL PHASE OF CARE AMONG ELDERLY WOMEN WITH BREAST CANCER. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. Vyas A, Madhavan SS, Sambamoorthi U, Pan XL, Regier M, Hazard HW, Kalidindi S

ALTERING CALCIUM INFLUX FOR SELECTIVE DESTRUCTION OF BREAST TUMOR. BMC CANCER. Yu HG, McLaughlin SL, Newman M, Brundage KM, Ammer AG, Martin KH, Coad JE

COLORECTAL CANCERTHE EFFICACY OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH STAGE II/III RESECTED RECTAL CANCER TREATED WITH NEOADJUVANT CHEMORADIATION THERAPY. AMERICAN JOURNAL OF CLINICAL ONCOLOGY. Ahn DH, Wu C, Wei L, Williams TM, Wuthrick E, Abdel-Misih S, Harzman A, Husain S, Schmidt C, Goldberg RM, Bekaii-Saab T

PRIMARY TUMOR SIDEDNESS AS PROGNOSTIC AND PREDICTIVE BIOMARKER IN METASTATIC COLORECTAL CANCER: FURTHER VALIDATION OF A POTENTIALLY PRACTICE-CHANGING VARIABLE. JAMA ONCOLOGY. Ciombor KK, Goldberg RM

PHASE I/II TRIAL OF LABETUZUMAB GOVITECAN (ANTI-CEACAM5/SN-38 ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH REFRACTORY OR RELAPSING METASTATIC COLORECTAL CANCER. JOURNAL OF CLINICAL ONCOLOGY. Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, Wegener WA, Sharkey RM, Govindan SV, Goldenberg DM, Berlin JD

ADJUVANT CHEMORADIOTHERAPY WITH EPIRUBICIN, CISPLATIN, AND FLUOROURACIL COMPARED WITH ADJUVANT CHEMORADIOTHERAPY WITH FLUOROURACIL AND LEUCOVORIN AFTER CURATIVE RESECTION OF GASTRIC CANCER: RESULTS FROM CALGB 80101 (ALLIANCE). JOURNAL OF CLINICAL ONCOLOGY. Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson DH, O’Reilly EM, Ciombor KK, Berg DJ, Meyerhardt JA, Mayer RJ

COMPREHENSIVE POPULATION-WIDE ANALYSIS OF LYNCH SYNDROME IN ICELAND REVEALS FOUNDER MUTATIONS IN MSH6 AND PMS2. NATURE COMMUNICATIONS. Haraldsdottir S, Rafnar T, Frankel WL, Einarsdottir S, Sigurdsson A, Hampel H, Snaebjornsson P, Masson G, Weng D, Arngrimsson R, Kehr B, Yilmaz A, Haraldsson S, Sulem P, Stefansson T, Shields PG, Sigurdsson F, Bekaii-Saab T, Moller PH, Steinarsdottir M, Alexiusdottir K, Hitchins M, Pritchard CC, de la Chapelle A, Jonasson JG, Goldberg RM, Stefansson K

FAMILY HISTORY OF COLORECTAL CANCER AND ITS IMPACT ON SURVIVAL IN PATIENTS WITH RESECTED STAGE III COLON CANCER: RESULTS FROM NCCTG TRIAL N0147 (ALLIANCE). JOURNAL OF GASTROINTESTINAL ONCOLOGY. Jansson-Knodell CL, Foster NR, Sargent DJ, Limburg PJ, Thibodeau SN, Smyrk TC, Sinicrope FA, Jahagirdar B, Goldberg RM, Alberts SR

Publications

BASIC CANCER RESEARCHINTERSTITIAL INORGANIC PHOSPHATE AS A TUMOR MICROENVIRONMENT MARKER FOR TUMOR PROGRESSION. SCIENTIFIC REPORTS. Bobko AA, Eubank TD, Driesschaert B, Dhimitruka I, Evans J, Mohammad R, Tchekneva EE, Dikov MM, Khramtsov VV

CONCURRENT LONGITUDINAL EPR MONITORING OF TISSUE OXYGENATION, ACIDOSIS, AND REDUCING CAPACITY IN MOUSE XENOGRAFT TUMOR MODELS. CELL BIOCHEMISTRY AND BIOPHYSICS. Bobko AA, Evans J, Denko NC, Khramtsov VV

BIALLELIC PMS2 MUTATION AND HETEROZYGOUS DICER1 MUTATION PRESENTING AS CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY WITH CORPUS CALLOSUM AGENESIS: CASE REPORT AND REVIEW OF LITERATURE. JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY. Cheyuo C, Radwan W, Ahn JS, Gyure K, Qaiser R, Tomboc P

PROGNOSTIC SIGNIFICANCE OF CORTICOTROPH STAINING IN RADIOSURGERY FOR NON-FUNCTIONING PITUITARY ADENOMAS: A MULTICENTER STUDY. JOURNAL OF NEURO-ONCOLOGY. Cohen-Inbar O, Xu Z, Lee CC, Wu CC, Chytka T, Silva D, Sharma M, Radwan H, Grills IS, Nguyen B, Siddiqui Z, Mathieu D, Iorio-Morin C, Wolf A, Cifarelli CP, Cifarelli DT, Lunsford LD, Kondziolka D, Sheehan JP

QUANTIFYING SPONTANEOUS METASTASIS IN A SYNGENEIC MOUSE MELANOMA MODEL USING REAL TIME PCR. ANALYST. Deng WT, McLaughlin SL, Klinke DJ

NITRO-TRIARYLMETHYL RADICAL AS DUAL OXYGEN AND SUPEROXIDE PROBE. CELL BIOCHEMISTRY AND BIOPHYSICS. Driesschaert B, Bobko AA, Khramtsov VV, Zweier JL

IMAGING THIOL REDOX STATUS IN MURINE TUMORS IN VIVO WITH RAPID-SCAN ELECTRON PARAMAGNETIC RESONANCE. JOURNAL OF MAGNETIC RESONANCE. Epel B, Sundramoorthy SV, Krzykawska-Serda M, Maggio MC, Tseytlin MP, Eaton GR, Eaton SS, Rosen GM, J PYK, Halpern HJ

ROLES OF GRAINYHEAD-LIKE TRANSCRIPTION FACTORS IN CANCER. ONCOGENE. Frisch SM, Farris JC, Pifer PM

THE EVOLUTION OF CLINICAL TRIALS IN ONCOLOGY: DEFINING WHO BENEFITS FROM NEW DRUGS USING INNOVATIVE STUDY DESIGNS. THE ONCOLOGIST. Goldberg RM, Wei L, Fernandez S

PHOSPHOLIPID BINDING TO THE FAK CATALYTIC DOMAIN IMPACTS FUNCTION. PLOS ONE. Hall JE, Schaller MD

DUAL TARGETING OF MESENCHYMAL AND AMOEBOID MOTILITY HINDERS METASTATIC BEHAVIOR. MOLECULAR CANCER RESEARCH. Jones BC, Kelley LC, Loskutov YV, Marinak KM, Kozyreva VK, Smolkin MB, Pugacheva EN

IN VIVO MOLECULAR EPR-BASED SPECTROSCOPY AND IMAGING OF TUMOR MICROENVIRONMENT AND REDOX USING FUNCTIONAL PARAMAGNETIC PROBES. ANTIOXIDANTS & REDOX SIGNALING. Khramtsov VV

EXCHANGE PHENOMENA IN THE ELECTRON PARAMAGNETIC RESONANCE SPECTRA OF THE NITROXYL AND TRITYL RADICALS: MULTIFUNCTIONAL SPECTROSCOPY AND IMAGING OF LOCAL CHEMICAL MICROENVIRONMENT. ANALYTICAL CHEMISTRY. Khramtsov VV, Bobko AA, Tseytlin MP, Driesschaert B

IN VIVO APPLICATION OF PROTON ELECTRON DOUBLE RESONANCE IMAGING. ANTIOXIDANTS & REDOX SIGNALING. Kishimoto S, Cherukuri MK, Khramtsov VV, Utsumi H, Lurie DJ

FEASIBILITY OF IN VIVO THREE-DIMENSIONAL T 2* MAPPING USING DICARBOXY-PROXYL AND CW-EPR-BASED SINGLE-POINT IMAGING. MAGMA. Kubota H, Komarov DA, Yasui H, Matsumoto S, Inanami O, Kirilyuk IA, Khramtsov VV, Hirata H

STABLE AND POTENT SELENOMAB-DRUG CONJUGATES. CELL CHEMICAL BIOLOGY. Li X, Nelson CG, Nair RR, Hazlehurst LA, Moroni T, Martinez-Acedo P, Nanna AR, Hymel D, Burke TR, Jr., Rader C

SPECIAL ISSUE: "MET AS ACTIONABLE TARGET IN CANCER THERAPY". ANNALS OF TRANSLATIONAL MEDICINE. Ma PC

AN EXPORTIN-1-DEPENDENT MICRORNA BIOGENESIS PATHWAY DURING HUMAN CELL QUIESCENCE. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. Martinez I, Hayes KE, Barr JA, Harold AD, Xie M, Bukhari SIA, Vasudevan S, Steitz JA, DiMaio D

IMPAIRED TISSUE OXYGENATION IN METABOLIC SYNDROME REQUIRES INCREASED MICROVASCULAR PERFUSION HETEROGENEITY. JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH. McClatchey PM, Wu F, Olfert IM, Ellis CG, Goldman D, Reusch JE, Frisbee JC

METERED CRYOSPRAY: A NOVEL UNIFORM, CONTROLLED, AND CONSISTENT IN VIVO APPLICATION OF LIQUID NITROGEN CRYOGENIC SPRAY. MEDICAL DEVICES (AUCKLAND, NZ). Mulcahey TI, Coad JE, Fan WL, Grasso DJ, Hanley BM, Hawkes HV, McDermott SA, O'Connor JP, Sheets EE, Vadala CJ

ENGINEERING CONCEPTS IN STEM CELL RESEARCH. BIOTECHNOLOGY JOURNAL. Narayanan K, Mishra S, Singh S, Pei M, Gulyas B, Padmanabhan P

NOTHING BUT NET: A REVIEW OF NEUROENDOCRINE TUMORS AND CARCINOMAS. NEOPLASIA. Oronsky B, Ma PC, Morgensztern D, Carter CA

TRIARYLMETHYL-BASED BIRADICAL AS A SUPEROXIDE PROBE. FREE RADICAL RESEARCH. Poncelet M, Driesschaert B, Bobko AA, Khramtsov VV

THE PROTEASOMAL ATPASES USE A SLOW BUT HIGHLY PROCESSIVE STRATEGY TO UNFOLD PROTEINS. FRONTIERS IN MOLECULAR BIOSCIENCES. Snoberger A, Anderson RT, Smith DM

PRECLINICAL POSITRON EMISSION TOMOGRAPHY SCANNER BASED ON A MONOLITHIC ANNULUS OF SCINTILLATOR: INITIAL DESIGN STUDY. JOURNAL OF MEDICAL IMAGING. Stolin AV, Martone PF, Jaliparthi G, Raylman RR

A SYSTEMATIC REVIEW OF EXERCISE SYSTEMATIC REVIEWS IN THE CANCER LITERATURE (2005-2017). PM & R: THE JOURNAL OF INJURY, FUNCTION, AND REHABILITATION. Stout NL, Baima J, Swisher AK, Winters-Stone KM, Welsh J

PERMEABILITY ACROSS A NOVEL MICROFLUIDIC BLOOD-TUMOR BARRIER MODEL. FLUIDS AND BARRIERS OF THE CNS. Terrell-Hall TB, Ammer AG, Griffith JI, Lockman PR

FULL CYCLE RAPID SCAN EPR DECONVOLUTION ALGORITHM. JOURNAL OF MAGNETIC RESONANCE. Tseytlin MP

CONCEPT OF PHASE CYCLING IN PULSED MAGNETIC RESONANCE USING SINUSOIDAL MAGNETIC FIELD MODULATION. ZEITSCHRIFT FUR PHYSIKALISCHE CHEMIE-INTERNATIONAL JOURNAL OF RESEARCH IN PHYSICAL CHEMISTRY & CHEMICAL PHYSICS. Tseytlin MP

ANALYTIC VALIDATION AND REAL-TIME CLINICAL APPLICATION OF AN AMPLICON-BASED TARGETED GENE PANEL FOR ADVANCED CANCER. ONCOTARGET. Wing MR, Reeser JW, Smith AM, Reeder M, Martin D, Jewell BM, Datta J, Miya J, Monk JP, Mortazavi A, Otterson GA, Goldberg RM, VanDeusen JB, Cole S, Dittmar K, Jaiswal S, Kinzie M, Waikhom S, Freud AG, Zhou XP, Chen W, Bhatt D, Roychowdhury S

A PHASE IB STUDY OF THE DUAL PI3K/MTOR INHIBITOR DACTOLISIB (BEZ235) COMBINED WITH EVEROLIMUS IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES. TARGETED ONCOLOGY. Wise-Draper TM, Moorthy G, Salkeni MA, Karim NA, Thomas HE, Mercer CA, Beg MS, O'Gara S, Olowokure O, Fathallah H, Kozma SC, Thomas G, Rixe O, Desai PB, Morris JC

26 27WVUMedicine.org/cancer Volume III 2018

WVU Cancer Institute EDUCATION The Signature

MISMATCH-REPAIR DEFICIENCY PREDICTS RESPONSE OF SOLID TUMORS TO PD-1 BLOCKADE. SCIENCE. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA, Jr.

A BLUEPRINT TO ADVANCE COLORECTAL CANCER IMMUNOTHERAPIES. CANCER IMMUNOOGYL RESEARCH. Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA, Jr., Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith WA, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O’Donnell-Tormey J, Roach N, Davis AQD, McAbee KE, Worrall S, Benson AB, 3rd

PREVALENCE AND SPECTRUM OF GERMLINE CANCER SUSCEPTIBILITY GENE MUTATIONS AMONG PATIENTS WITH EARLY-ONSET COLORECTAL CANCER. JAMA ONCOLOGY. Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM, Paskett ED, Shields PG, Freudenheim JL, Stanich PP, Lattimer I, Arnold M, Liyanarachchi S, Kalady M, Heald B, Greenwood C, Paquette I, Prues M, Draper DJ, Lindeman C, Kuebler JP, Reynolds K, Brell JM, Shaper AA, Mahesh S, Buie N, Weeman K, Shine K, Haut M, Edwards J, Bastola S, Wickham K, Khanduja KS, Zacks R, Pritchard CC, Shirts BH, Jacobson A, Allen B, de la Chapelle A, Hampel H, Ohio Colorectal Cancer Prevention Initiative Study G

TREATMENT AND SURVIVAL OF MEDICARE BENEFICIARIES WITH COLORECTAL CANCER: A COMPARATIVE ANALYSIS BETWEEN A RURAL STATE CANCER REGISTRY AND NATIONAL DATA. POPULATION HEALTH MANAGEMENT. Rane PB, Madhavan SS, Sambamoorthi U, Sita K, Kurian S, Pan X

CLINICAL CALCULATOR FOR EARLY MORTALITY IN METASTATIC COLORECTAL CANCER: AN ANALYSIS OF PATIENTS FROM 28 CLINICAL TRIALS IN THE AIDE ET RECHERCHE EN CANCEROLOGIE DIGESTIVE DATABASE. JOURNAL OF CLINICAL ONCOLOGY. Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ, Program ACT

ASSOCIATION OF DNA MISMATCH REPAIR AND MUTATIONS IN BRAF AND KRAS WITH SURVIVAL AFTER RECURRENCE IN STAGE III COLON CANCERS : A SECONDARY ANALYSIS OF 2 RANDOMIZED CLINICAL TRIALS. JAMA ONCOLOGY. Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR

PERSONALIZING SURVIVAL PREDICTIONS IN ADVANCED COLORECTAL CANCER: THE ARCAD NOMOGRAM PROJECT. JOURNAL OF THE NATIONAL CANCER INSTITUTE. Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams RA, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs CS, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR, Group FAeReCD

EFFECT OF FIRST-LINE CHEMOTHERAPY COMBINED WITH CETUXIMAB OR BEVACIZUMAB ON OVERALL SURVIVAL IN PATIENTS WITH KRAS WILD-TYPE ADVANCED OR METASTATIC COLORECTAL CANCER: A RANDOMIZED CLINICAL TRIAL. JAMA: JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O’Neil BH, Atkins JN, Berry S, Polite BN, O’Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB, 3rd, Mulkerin DL, Mayer RJ, Blanke C

ROLE OF DEFICIENT DNA MISMATCH REPAIR STATUS IN PATIENTS WITH STAGE III COLON CANCER TREATED WITH FOLFOX ADJUVANT CHEMOTHERAPY: A POOLED ANALYSIS FROM 2 RANDOMIZED CLINICAL TRIALS. JAMA ONCOLOGY. Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA

GASTROINTESTINAL CANCERHPSLYD INDUCING CDX2 AND VIL1 EXPRESSION MEDIATED THROUGH TCTP PROTEIN MAY CONTRIBUTE TO INTESTINAL METAPLASIA IN THE STOMACH. SCIENTIFIC REPORTS. Li Q, Zhu Y, Liu J, Yu X, Chen M, Dong N, Gong Y, Yuan Y

GYNECOLOGIC & URINARY CANCERINHIBITORY EFFECT OF BLACK TEA PIGMENTS, THEAFLAVIN3/3’-GALLATE AGAINST CISPLATIN-RESISTANT OVARIAN CANCER CELLS BY INDUCING APOPTOSIS AND G1 CELL CYCLE ARREST. INTERNATIONAL JOURNAL OF ONCOLOGY. Pan H, Wang F, Rankin GO, Rojanasakul Y, Tu Y, Chen YC

3-HYDROXYTERPHENYLLIN, A NATURAL FUNGAL METABOLITE, INDUCES APOPTOSIS AND S PHASE ARREST IN HUMAN OVARIAN CARCINOMA CELLS. INTERNATIONAL JOURNAL OF ONCOLOGY. Wang YM, Compton C, Rankin GO, Cutler SJ, Rojanasakul Y, Tu Y, Chen YC

ANTI-PROLIFERATIVE EFFECT AND CELL CYCLE ARREST INDUCED BY SAPONINS EXTRACTED FROM TEA (CAMELLIA SINENSIS) FLOWER IN HUMAN OVARIAN CANCER CELLS. JOURNAL OF FUNCTIONAL FOODS. Wang YM, Ren N, Rankin GO, Li B, Rojanasakul Y, Tu YY, Chen YC

THE FIRST AMERICAN CANCER PATIENT TO RECEIVE DICYCLOPLATIN CHEMOTHERAPY: A CASE REPORT. JOURNAL OF CANCER RESEARCH & THERAPY. Yu JJ, Salkini MW, Jiao S, Hogan TF, Guo Y, Liang X, Yang B, Zhang L, Gyure K

HEMATOLOGIC CANCERAUTOLOGOUS TRANSPLANTATION IN FOLLICULAR LYMPHOMA WITH EARLY THERAPY FAILURE: A NLCS AND CIBMTR ANALYSIS. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Casulo C, Friedberg JW, Ahn KW, Flowers CR, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf MD, Chen AI, Choe H, Cohen JB, Copelan EA, Farooq U, Fenske TS, Freytes CO, Gaballa S, Ganguly S, Jethava Y, Kamble RT, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, Solh M, Sureda A, William B, Cumpston AD, Zelenetz AD, Link BK, Hamadani M

IMMUNE-DDR CROSSTALK IN PRE-LEUKEMIA STEM CELLS. ONCOTARGET. Wu L, Cole A, Du W

EMERGING COMBINATION THERAPIES FOR THE MANAGEMENT OF MULTIPLE MYELOMA: THE ROLE OF ELOTUZUMAB. CANCER MANAGEMENT AND RESEARCH. Chen WC, Kanate AS, Craig M, Petros WP, Hazlehurst LA

EVALUATION OF SERUM POSACONAZOLE CONCENTRATIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES RECEIVING POSACONAZOLE SUSPENSION COMPARED TO THE DELAYED-RELEASE TABLET FORMULATION. LEUKEMIA RESEARCH AND TREATMENT. Belling M, Kanate AS, Shillingburg A, Lu X, Wen S, Shah N, Craig M, Cumpston AD

SELECTIVE INHIBITION OF MATRIX METALLOPROTEINASE-2 IN THE MULTIPLE MYELOMA-BONE MICROENVIRONMENT. ONCOTARGET. Shay G, Tauro M, Loiodice F, Tortorella P, Sullivan DM, Hazlehurst LA, Lynch CC

OUTCOMES OF SIX-DOSE HIGH-DOSE CYTARABINE AS A SALVAGE REGIMEN FOR PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA. ADVANCES IN HEMATOLOGY. Anders B, Veltri L, Kanate AS, Shillingburg A, Shah N, Craig M, Cumpston AD

MTI-101 TREATMENT INDUCING ACTIVATION OF STIM1 AND TRPC1 EXPRESSION IS A DETERMINANT OF RESPONSE IN MULTIPLE MYELOMA. SCIENTIFIC REPORTS. Emmons MF, Anreddy N, Cuevas J, Steinberger K, Yang S, McLaughlin ML, Silva AS, Hazlehurst LA

PERSISTENT RESPONSE OF FANCONI ANEMIA HAEMATOPOIETIC STEM AND PROGENITOR CELLS TO OXIDATIVE STRESS. CELL CYCLE. Li Y, Amarachintha S, Wilson AF, Li X, Du W

IN VIVO RNAI SCREEN UNVEILS PPARGAMMA AS A REGULATOR OF HEMATOPOIETIC STEM CELL HOMEOSTASIS. STEM CELL REPORTS. Sertorio M, Du W, Amarachintha S, Wilson AF, Pang Q

RECIPIENT IMMUNE-MODULATION WITH ATORVASTATIN FOR ACUTE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOLLOWING ALLOGENEIC TRANSPLANTATION. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D’Souza A, Fenske TS, Cumpston AD, Bunner P, Craig M, Horowitz MM, Hamadani M

FANCD2 IN VIVO INTERACTION NETWORK REVEALS A NON-CANONICAL ROLE IN MITOCHONDRIAL FUNCTION. SCIENTIFIC REPORTS. Zhang T, Du W, Wilson AF, Namekawa SH, Andreassen PR, Meetei AR, Pang Q

PLASMABLASTIC LYMPHOMA VERSUS PLASMABLASTIC MYELOMA: AN ONGOING DIAGNOSTIC DILEMMA. JOURNAL OF CLINICAL PATHOLOGY. Ahn JS, Okal R, Vos JA, Smolkin M, Kanate AS, Rosado FG

ANALYSIS OF PERIPHERAL T-CELL LYMPHOMA DIAGNOSTIC WORKUP IN THE UNITED STATES. CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA. Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig M, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM

TREATMENT OF SEVERE MUCOSITIS PAIN WITH ORAL KETAMINE MOUTHWASH. SUPPORTIVE CARE IN CANCER. Shillingburg A, Kanate AS, Hamadani M, Wen SJ, Craig M, Cumpston AD

UBIQUITINATION OF HNRNPA1 BY TRAF6 LINKS CHRONIC INNATE IMMUNE SIGNALING WITH MYELODYSPLASIA. NATURE IMMUNOLOGY. Fang J, Bolanos LC, Choi K, Liu X, Christie S, Akunuru S, Kumar R, Wang D, Chen X, Greis KD, Stoilov P, Filippi MD, Maciejewski JP, Garcia-Manero G, Weirauch MT, Salamonis N, Geiger H, Zheng Y, Starczynowski DT

A PROSPECTIVE COHORT STUDY OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA IN THE UNITED STATES. CANCER. Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig M, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM

LONG-TERM OUTCOMES AFTER THIOTEPA-BASED HIGH-DOSE THERAPY (HDT) AND AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (AUTO-HCT) IN NON-HODGKIN LYMPHOMA (NHL). BONE MARROW TRANSPLANTATION. Shah N, Rauenzahn S, Veltri L, Wen S, Craig M, Hamadani M, Kanate AS, Cumpston AD

THE IMMUNE RECEPTOR TREM1 COOPERATES WITH DIMINISHED DNA DAMAGE RESPONSE TO INDUCE PRELEUKEMIC STEM CELL EXPANSION. LEUKEMIA. Du W, Amarachintha S, Wilson A, Pang Q

TARGETING INTRINSIC AND EXTRINSIC VULNERABILITIES FOR THE TREATMENT OF MULTIPLE MYELOMA. JOURNAL OF CELLULAR BIOCHEMISTRY. Anreddy N, Hazlehurst LA

LUNG CANCERDURABLE NEAR-COMPLETE RESPONSE TO ANTI-PD-1 CHECKPOINT IMMUNOTHERAPY IN A REFRACTORY MALIGNANT SOLITARY FIBROUS TUMOR OF THE PLEURA. CASE REPORTS IN ONCOLOGY. Boothe JT, Budd GT, Smolkin MB, Ma PC

CO-ACTIVATION OF STAT3 AND YES-ASSOCIATED PROTEIN 1 (YAP1) PATHWAY IN EGFR-MUTANT NSCLC. JOURNAL OF THE NATIONAL CANCER INSTITUTE. Chaib I, Karachaliou N, Pilotto S, Servat CC, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, Cardona AF, Vivanco GL, Vergnenegre A, Sanchez JM, Provencio M, Reguart N, Zhou C, Cao P, Ma PC, Bivona TG, Rosell R

NANOPARTICLES-INDUCED APOPTOSIS OF HUMAN AIRWAY EPITHELIUM IS MEDIATED BY PRONGF/P75NTR SIGNALING. JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH. PART A. Chakraborty S, Castranova V, Perez MK, Piedimonte G

SYNERGISTIC EFFECTS OF ENGINEERED NANOPARTICLES AND ORGANICS RELEASED FROM LASER PRINTERS USING NANO-ENABLED TONERS: POTENTIAL HEALTH IMPLICATIONS FROM EXPOSURES TO THE EMITTED ORGANIC AEROSOL. ENVIRONMENTAL SCIENCE. NANO. Chalbot MCG, Pirela SV, Schifman L, Kasaraneni V, Oyanedel-Craver V, Bello D, Castranova V, Qian Y, Thomas T, Kavouras IG, Demokritou P

MESOTHELIN PROMOTES EPITHELIAL-TO-MESENCHYMAL TRANSITION AND TUMORIGENICITY OF HUMAN LUNG CANCER AND MESOTHELIOMA CELLS. MOLECULAR CANCER. He X, Wang LY, Riedel H, Wang K, Yang Y, Dinu CZ, Rojanasakul Y

ANTI-TUMOR EFFECTS OF CARDIAC GLYCOSIDES ON HUMAN LUNG CANCER CELLS AND LUNG TUMORSPHERES. JOURNAL OF CELLULAR PHYSIOLOGY. Kaushik V, Yakisich JS, Azad N, Kulkarni YM, Venkatadri R, Wright C, Rojanasakul Y, Iyer AK

POTENTIAL TOXICITY AND UNDERLYING MECHANISMS ASSOCIATED WITH PULMONARY EXPOSURE TO IRON OXIDE NANOPARTICLES: CONFLICTING LITERATURE AND UNCLEAR RISK. NANOMATERIALS (BASEL). Kornberg TG, Stueckle TA, Antonini JA, Rojanasakul Y, Castranova V, Yang Y, Wang LY

ROLE OF EPITHELIAL-MESENCHYMAL TRANSITION (EMT) AND FIBROBLAST FUNCTION IN CERIUM OXIDE NANOPARTICLES-INDUCED LUNG FIBROSIS. TOXICOLOGY AND APPLIED PHARMACOLOGY. Ma J, Bishoff B, Mercer RR, Barger MW, Schwegler-Berry D, Castranova V

NAVIGATING THE “NO MAN’S LAND” OF TKI-FAILED EGFR-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC): A REVIEW. NEOPLASIA. Oronsky B, Ma PC, Reid TR, Cabrales P, Lybeck M, Oronsky A, Oronsky N, Carter CA

TRACKING MET DE-ADDICTION IN LUNG CANCER: A ROAD TOWARDS THE ONCOGENIC TARGET. CANCER TREATMENT REVIEWS. Pilotto S, Carbognin L, Karachaliou N, Ma PC, Rosell R, Tortora G, Bria E

LUNG BIOACTIVITY OF VAPOR GROWN CARBON NANOFIBERS. NANOIMPACT. Porter DW, Orandle M, Mercer RR, Wu NQ, Zheng P, Chen BT, Holian A, Andrew ME, Leonard S, Wolfarth M, Friend S, Battelli LA, Hamilton RF, Hagiwara Y, Koyama T, Castranova V

DETACHMENT-INDUCED E-CADHERIN EXPRESSION PROMOTES 3D TUMOR SPHEROID FORMATION BUT INHIBITS TUMOR FORMATION AND METASTASIS OF LUNG CANCER CELLS. AMERICAN JOURNAL OF PHYSIOLOGY. CELL PHYSIOLOGY. Powan P, Luanpitpong S, He X, Rojanasakul Y, Chanvorachote P

SILICA INHALATION ALTERED TELOMERE LENGTH AND GENE EXPRESSION OF TELOMERE REGULATORY PROTEINS IN LUNG TISSUE OF RATS. SCIENTIFIC REPORTS. Shoeb M, Joseph P, Kodali V, Mustafa G, Farris BY, Umbright C, Roberts JR, Erdely A, Antonini JM

EVALUATION OF TUMORIGENIC POTENTIAL OF CEO2 AND FE2O3 ENGINEERED NANOPARTICLES BY A HUMAN CELL IN VITRO SCREENING MODEL. NANOIMPACT. Stueckle TA, Davidson DC, Derk R, Kornberg TG, Schwegler-Berry D, Pirela SV, Deloid G, Demokritou P, Luanpitpong S, Rojanasakul Y, Wang LY

EFFECT OF SURFACE FUNCTIONALIZATIONS OF MULTI-WALLED CARBON NANOTUBES ON NEOPLASTIC TRANSFORMATION POTENTIAL IN PRIMARY HUMAN LUNG EPITHELIAL CELLS. NANOTOXICOLOGY. Stueckle TA, Davidson DC, Derk R, Wang P, Friend S, Schwegler-Berry DE, Zheng P, Wu NQ, Castranova V, Rojanasakul Y, Wang LY

28 WVUMedicine.org/cancer

WVU Cancer Institute EDUCATION PATIENT INFORMATION

For information on patient services at the WVU Cancer Institute, call our care team at 877-427-2894 or visit WVUMedicine.org/cancer.

CLINICAL TRIALSFor information on current clinical trials at the WVU Cancer Institute, contact the clinical trials team by e-mail at cancertrialsinfo@hsc.wvu.edu.

DONOR INFORMATIONFor information on supporting programs at the WVU Cancer Institute, please contact:

Office of PhilanthropyScarlett K. Schneider, PhDSenior Director of Development304-293-7732scarlett.schneider@hsc.wvu.eduWVUCancer.org/give

SOCIAL MEDIA

@WVUMedicine

EDITORAngela Knopf, Manager of Media Relations

DESIGNERKatie Sickman

TONY CONDIAVice President of Marketing and Communications

AMY JOHNSDirector of Public Affairs and Creative Services

The Signature is published by WVU Medicine on behalf of the WVU Cancer Institute.

All correspondence related to The Signature should be addressed to:

WVU Medicine Marketing and Communications communications@wvumedicine.org

Articles and photos may be reprinted with permission.

Visit the WVU Cancer Institute website at WVUMedicine.org/cancer.

© 2018 WVU Medicine

EDITORIAL BOARD

Richard M. Goldberg, MDDIRECTOR

Laura Gibson, PhDDEPUTY DIRECTOR

Hannah Hazard, MDDIRECTOR OF CLINICAL SERVICES

LOCATIONSMARY BABB RANDOLPH CANCER CENTERMORGANTOWN, WV304-598-4500 or 877-427-2894

BETTY PUSKAR BREAST CARE CENTERMORGANTOWN, WV304-293-8012

UNIVERSITY HEALTHCARE REGIONAL CANCER CENTERMARTINSBURG, WV304-267-1944

CAMDEN CLARK REGIONAL CANCER CENTERPARKERSBURG, WV304-424-2256

WVU CANCER INSTITUTE AT GARRETT REGIONAL MEDICAL CENTEROAKLAND, MD301-533-4222

FAIRMONT REGIONAL CANCER CENTERFAIRMONT, WV304-366-9999

DAVIS MEDICAL CENTER CANCER CARE CENTERELKINS, WV304-637-3640

WVU CANCER INSTITUTE AT REYNOLDS MEMORIAL HOSPITALGLEN DALE, WV304-843-3302

SOX9 REGULATES CANCER STEM-LIKE PROPERTIES AND METASTATIC POTENTIAL OF SINGLE-WALLED CARBON NANOTUBE-EXPOSED CELLS. SCIENTIFIC REPORTS. Voronkova MA, Luanpitpong S, Rojanasakul LW, Castranova V, Dinu CZ, Riedel H, Rojanasakul Y

TOXICITY EVALUATIONS OF NANOCLAYS AND THERMALLY DEGRADED BYPRODUCTS THROUGH SPECTROSCOPICAL AND MICROSCOPICAL APPROACHES. BIOCHIMICA ET BIOPHYSICA ACTA (BBA)-GENERAL SUBJECTS. Wagner A, Eldawud R, White A, Agarwal S, Stueckle TA, Sierros K, Rojanasakul Y, Gupta RK, Dinu CZ

EARLY ASSESSMENT AND CORRELATIONS OF NANOCLAY’S TOXICITY TO THEIR PHYSICAL AND CHEMICAL PROPERTIES. ACS APPLIED MATERIALS & INTERFACES. Wagner A, White AP, Stueckle TA, Banerjee D, Sierros KA, Rojanasakul Y, Agarwal S, Gupta RK, Dinu CZ

CARBON NANOTUBES INDUCED FIBROGENESIS ON NANOSTRUCTURED SUBSTRATES. ENVIRONMENTAL SCIENCE. NANO. Wang K, He X, Linthicum W, Mezan R, Wang LY, Rojanasakul Y, Wen Q, Yang Y

INDUCTION OF SLUG BY CHRONIC EXPOSURE TO SINGLE-WALLED CARBON NANOTUBES PROMOTES TUMOR FORMATION AND METASTASIS. CHEMICAL RESEARCH IN TOXICOLOGY. Wang P, Voronkova MA, Luanpitpong S, He X, Riedel H, Dinu CZ, Wang LY, Rojanasakul Y

AXL-GAS6 EXPRESSION CAN PREDICT FOR ADVERSE PROGNOSIS IN NON-SMALL CELL LUNG CANCER WITH BRAIN METASTASES. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. Wu X, Ma W, Zhou Q, Yan H, Lim ZF, Huang M, Deng C, Yu X, Su H, Komo S, Yang H, Zhang X, Wen SJ, Zhang Z, Ma PC

PREVENTION CONTROL & EDUCATION CANCER RESEARCHDEPRESSION TREATMENT AMONG ELDERLY MEDICARE BENEFICIARIES WITH INCIDENT CASES OF CANCER AND NEWLY DIAGNOSED DEPRESSION. PSYCHIATRIC SERVICES. Alwhaibi M, Madhavan SS, Bias TK, Kelly KM, Walkup J, Sambamoorthi U

CANCER TYPE AND RISK OF NEWLY DIAGNOSED DEPRESSION AMONG ELDERLY MEDICARE BENEFICIARIES WITH INCIDENT BREAST, COLORECTAL, AND PROSTATE CANCERS. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. Alwhaibi M, Sambamoorthi U, Madhavan SS, Bias TK, Kelly KM, Walkup J

DEPRESSION TREATMENT AND HEALTHCARE EXPENDITURES AMONG ELDERLY MEDICARE BENEFICIARIES WITH NEWLY-DIAGNOSED DEPRESSION AND INCIDENT BREAST, COLORECTAL OR PROSTATE CANCER. PSYCHO-ONCOLOGY. Alwhaibi M, Sambamoorthi U, Madhavan SS, Walkup JT

PHYSICAL ACTIVITY AND QUIT MOTIVATION MODERATORS OF ADOLESCENT SMOKING REDUCTION. AMERICAN JOURNAL OF HEALTH BEHAVIOR. Blank MD, Ferris KA, Metzger A, Gentzler A, Duncan C, Jarrett T, Dino GA

USE OF MULTISOURCE FEEDBACK TO IMPROVE INTERDISCIPLINARY CARE AMONG ONCOLOGISTS. JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY. Catherman KA, Grey C, Mattes MD

NONADHERENCE TO STATINS AND ANTIHYPERTENSIVES AND HOSPITALIZATIONS AMONG ELDERLY MEDICARE BENEFICIARIES WITH INCIDENT CANCER. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. Chopra I, Dwibedi N, Mattes MD, Tan X, Findley PA, Sambamoorthi U

TUMOR BOARD SHADOWING FOR MEDICAL STUDENTS AS A MEANS OF EARLY EXPOSURE TO MULTIDISCIPLINARY ONCOLOGY EDUCATION. JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY. Mattes MD, Gerbo R, Dattola RM

METHODS OF ACADEMIC COURSE PLANNING FOR CANCER BIOLOGY PH.D. STUDENTS TO ENHANCE KNOWLEDGE OF CLNICAL ONCOLOGY. CANCER RESEARCH. Mattes MD, Swart E, Markwell SM, Wen S, Vona-Davis LC

STUDENT PERSPECTIVES ON ONCOLOGY CURRICULA AT UNITED STATES MEDICAL SCHOOLS. JOURNAL OF CANCER EDUCATION. Neeley BC, Golden DW, Brower JV, Braunstein SE, Hirsch AE, Mattes MD

INCORPORATING HEALTH LITERACY SCREENING INTO PATIENTS’ HEALTH ASSESSMENT. CLINICAL NURSING RESEARCH. Sand-Jecklin K, Daniels CS, Lucke-Wold AN

WHAT’S IN A NAME? ELIFE. Schaller MD, McDowell G, Porter A, Shippen D, Friedman KL, Gentry MS, Serio TR, Sundquist WI

TRENDS IN UTILIZATION OF SMOKING CESSATION AGENTS BEFORE AND AFTER THE PASSAGE OF FDA BOXED WARNING IN THE UNITED STATES. DRUG AND ALCOHOL DEPENDENCE. Shah D, Shah A, Tan X, Sambamoorthi U

ATTITUDES OF RADIATION ONCOLOGISTS TOWARD PALLIATIVE AND SUPPORTIVE CARE IN THE UNITED STATES: REPORT ON NATIONAL MEMBERSHIP SURVEY BY THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO). PRACTICAL RADIATION ONCOLOGY. Wei RL, Mattes MD, Yu J, Thrasher A, Shu HK, Paganetti H, De Los Santos J, Koontz B, Abraham C, Balboni T

SKIN CANCERACUTE ENCEPHALOPATHY WITH COMBINATION DABRAFENIB/TRAMETINIB THERAPY. JOURNAL OF ONCOLOGY PHARMACY PRACTICE. Cooper J, Kodali D, Higa GM

TARGETING MELANOMA WITH FRONT-LINE THERAPY DOES NOT ABROGATE NODAL-EXPRESSING TUMOR CELLS. LABORATORY INVESTIGATION. Hendrix MJ, Kandela I, Mazar AP, Seftor EA, Seftor RE, Margaryan NV, Strizzi L, Murphy GF, Long GV, Scolyer RA

EFFECTS OF TITANIUM DIOXIDE NANOPARTICLES ON HUMAN KERATINOCYTES. DRUG AND CHEMICAL TOXICOLOGY. Wright C, Iyer AK, Wang LY, Wu NQ, Yakisich JS, Rojanasakul Y, Azad N

MELANOMA EXOSOMES DELIVER A COMPLEX BIOLOGICAL PAYLOAD THAT UPREGULATES PTPN11 TO SUPPRESS T LYMPHOCYTE FUNCTION. PIGMENT CELL & MELANOMA RESEARCH. Wu Y, Deng WT, McGinley EC, Klinke DJ

P.O. Box 9083Morgantown, WV 26506-9083